
    
      Pre- and post-menopausal women age â‰¥ 18 years with unresectable, ER-positive and/or
      PR-positive and HER2-negative locally-recurrent or metastatic breast cancer (mBC) with no
      prior line of chemotherapy in the metastatic setting, and that have shown progression while
      on an aromatase inhibitor-containing regimen in the metastatic setting or within six months
      from last aromatase inhibitor dose in the adjuvant setting. Patients must have received at
      least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting.
      Subjects must have adequate bone marrow and creatinine clearance functions.
    
  